LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 28

Search options

  1. Article ; Online: Remdesivir for the Treatment of Covid-19 - Preliminary Report.

    Gillenwater, Samantha / Rahaghi, Franck / Hadeh, Anas

    The New England journal of medicine

    2020  Volume 383, Issue 10, Page(s) 992

    MeSH term(s) Adenosine Monophosphate/analogs & derivatives ; Alanine/analogs & derivatives ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/drug therapy ; Humans ; Pandemics ; Pneumonia, Viral ; SARS-CoV-2 ; COVID-19 Drug Treatment
    Chemical Substances remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Alanine (OF5P57N2ZX)
    Keywords covid19
    Language English
    Publishing date 2020-07-10
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc2022236
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Remdesivir for the Treatment of Covid-19 - Preliminary Report.

    McMahon, James H / Udy, Andrew / Peleg, Anton Y

    The New England journal of medicine

    2020  Volume 383, Issue 10, Page(s) 992–993

    MeSH term(s) Adenosine Monophosphate/analogs & derivatives ; Alanine/analogs & derivatives ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/drug therapy ; Humans ; Pandemics ; Pneumonia, Viral ; SARS-CoV-2 ; COVID-19 Drug Treatment
    Chemical Substances remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Alanine (OF5P57N2ZX)
    Keywords covid19
    Language English
    Publishing date 2020-07-10
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc2022236
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Remdesivir for the Treatment of Covid-19 - Preliminary Report.

    McCaw, Zachary R / Kim, Dae H / Wei, Lee-Jen

    The New England journal of medicine

    2020  Volume 383, Issue 10, Page(s) 993

    MeSH term(s) Adenosine Monophosphate/analogs & derivatives ; Alanine/analogs & derivatives ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/drug therapy ; Humans ; Pandemics ; Pneumonia, Viral ; SARS-CoV-2 ; COVID-19 Drug Treatment
    Chemical Substances remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Alanine (OF5P57N2ZX)
    Keywords covid19
    Language English
    Publishing date 2020-07-10
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc2022236
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Remdesivir for the Treatment of Covid-19 - Preliminary Report.

    Olalla, Julián

    The New England journal of medicine

    2020  Volume 383, Issue 10, Page(s) 993–994

    MeSH term(s) Adenosine Monophosphate/analogs & derivatives ; Alanine/analogs & derivatives ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/drug therapy ; Humans ; Pandemics ; Pneumonia, Viral ; SARS-CoV-2 ; COVID-19 Drug Treatment
    Chemical Substances remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Alanine (OF5P57N2ZX)
    Keywords covid19
    Language English
    Publishing date 2020-07-10
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc2022236
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.

    Beigel, John H / Tomashek, Kay M / Dodd, Lori E

    The New England journal of medicine

    2020  Volume 383, Issue 10, Page(s) 994

    MeSH term(s) Adenosine Monophosphate/analogs & derivatives ; Alanine/analogs & derivatives ; Betacoronavirus ; Coronavirus Infections/drug therapy ; Humans ; Pandemics ; Pneumonia, Viral
    Chemical Substances remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Alanine (OF5P57N2ZX)
    Keywords covid19
    Language English
    Publishing date 2020-07-10
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc2022236
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Book ; Online: Remdesivir for the Treatment of Covid-19 - Preliminary Report

    Beigel, John H. / Finberg, Robert W. / ACTT-1 Study Group Members

    COVID-19 Publications by UMMS Authors

    2020  

    Abstract: ... of coronavirus disease 2019 (Covid-19), none have yet been shown to be efficacious. METHODS: We conducted ... with Covid-19 with evidence of lower respiratory tract involvement. Patients were randomly assigned ... to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection. (Funded ...

    Abstract BACKGROUND: Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), none have yet been shown to be efficacious. METHODS: We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults hospitalized with Covid-19 with evidence of lower respiratory tract involvement. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only. RESULTS: A total of 1063 patients underwent randomization. The data and safety monitoring board recommended early unblinding of the results on the basis of findings from an analysis that showed shortened time to recovery in the remdesivir group. Preliminary results from the 1059 patients (538 assigned to remdesivir and 521 to placebo) with data available after randomization indicated that those who received remdesivir had a median recovery time of 11 days (95% confidence interval [CI], 9 to 12), as compared with 15 days (95% CI, 13 to 19) in those who received placebo (rate ratio for recovery, 1.32; 95% CI, 1.12 to 1.55; P < 0.001). The Kaplan-Meier estimates of mortality by 14 days were 7.1% with remdesivir and 11.9% with placebo (hazard ratio for death, 0.70; 95% CI, 0.47 to 1.04). Serious adverse events were reported for 114 of the 541 patients in the remdesivir group who underwent randomization (21.1%) and 141 of the 522 patients in the placebo group who underwent randomization (27.0%). CONCLUSIONS: Remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACCT-1 ClinicalTrials.gov number, NCT04280705.).
    Keywords COVID-19 ; coronavirus disease 2019 ; treatment ; remdesivir ; clinical trial ; Adaptive COVID-19 Treatment Trial (ACTT) ; Clinical Trials ; Immunology and Infectious Disease ; Infectious Disease ; Respiratory Tract Diseases ; Therapeutics ; Virus Diseases ; covid19
    Subject code 610
    Publishing date 2020-05-22T07:00:00Z
    Publisher eScholarship@UMMS
    Publishing country us
    Document type Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top